The evolving role and utility of off-label drug use in multiple myeloma

The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 19 drug approvals and at least eight different active classes. The advances seen in MM therapy have rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoeckle, James H, Davies, Faith E, Williams, Louis, Boyle, Eileen M, Morgan, Gareth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400732/
https://www.ncbi.nlm.nih.gov/pubmed/36046752
http://dx.doi.org/10.37349/etat.2021.00050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400732/
https://www.ncbi.nlm.nih.gov/pubmed/36046752
http://dx.doi.org/10.37349/etat.2021.00050

Ejemplares similares